FDA: Ibogaine Research Public Input on Trial Design

• The FDA has issued a Request for Information (RFI) to gather public input on the design of early-phase clinical trials for ibogaine drug products.
• The RFI seeks comments on specific protocol elements, including dose selection, care setting, safety monitoring, and eligibility criteria for ibogaine clinical trials design.
• This initiative is part of a broader federal effort, including an executive order and existing guidance, to accelerate research into psychedelic medicine.
• Federal agencies are supporting ibogaine and its derivatives, with research prioritized for opioid use disorder and post-traumatic stress disorder.
• The public has until November 20, 2026, to submit comments via Docket No. FDA-2026-N-10429, offering a key opportunity to influence future regulatory pathways.

This initiative presents a critical opportunity for pharmaceutical companies, research institutions, and investors in the psychedelic medicine space to directly influence the FDA's regulatory approach to ibogaine clinical trials.

The U.S. Food and Drug Administration (FDA) has initiated a Request for Information (RFI) to gather public input on proposed methodologies for designing early-phase clinical trials involving ibogaine drug products. This crucial step aims to inform the agency's understanding of this novel compound, particularly given the serious conditions and unmet needs of patients who might benefit from ibogaine treatments. The FDA ibogaine research public input is specifically sought on various critical protocol elements, including appropriate dose selection and escalation strategies, the optimal care setting for administration, robust safety monitoring procedures, patient eligibility criteria, clear stopping rules for trials, and comprehensive safety oversight mechanisms.

This RFI is designed to solicit comments, data, and comprehensive information across four primary areas, which will collectively help the FDA better understand the potential uses, benefits, and inherent risks associated with ibogaine drug products. The insights gained are expected to significantly inform and shape future approaches to ibogaine drug development, ensuring that patient safety remains paramount while fostering rigorous scientific investigation into promising new treatments.

This latest FDA action aligns with a broader federal commitment to accelerate research into psychedelic medicine, stemming from President Trump’s April 2026 executive order on Accelerating Medical Treatments for Serious Mental Illness. Dr. Michael Davis, Director of the FDA Center for Drug Evaluation and Research, underscored the importance of this initiative, stating that patients with serious conditions unresponsive to existing treatments deserve rigorous scientific exploration of new approaches. He acknowledged both the significant scientific questions and serious safety concerns surrounding ibogaine, emphasizing the need for high-quality data and input to guide clinical research with patient safety as the top priority.

Further demonstrating this whole-of-government approach to psychedelic drug development FDA, the agency previously issued its finalized guidance for industry, "Psychedelic Drugs: Considerations for Clinical Investigations," in July 2026, offering general considerations for sponsors. Beyond ibogaine itself, the FDA has also permitted an early-phase clinical study for noribogaine hydrochloride, a derivative of ibogaine, to proceed under an Investigational New Drug (IND) application, exploring its potential as a treatment for alcohol use disorder. Concurrently, the Department of Health and Human Services (HHS), through its Advanced Research Projects Agency for Health (ARPA-H), is funding a program to collect safety and efficacy data from early-phase clinical trials, while the National Institute on Drug Abuse (NIDA) is specifically funding ibogaine research for the potential treatment of opioid use disorder (OUD). Based on available data and the severity of these conditions, HHS is prioritizing federally supported research for adults with OUD and post-traumatic stress disorder (PTSD).

The public is afforded a 45-day window following the RFI's publication in the Federal Register to submit comments, data, or other relevant information. This initiative presents a critical opportunity for pharmaceutical companies, research institutions, and investors in the psychedelic medicine space to directly influence the FDA's regulatory approach to ibogaine clinical trials. Submitting comprehensive comments can significantly help shape future drug development pathways and compliance requirements for these novel treatments for mental health and substance use disorders.

Stakeholders are strongly encouraged to submit their input electronically via regulations.gov by searching for Docket No. FDA-2026-N-10429. For those preferring traditional methods, written or paper submissions can be mailed to: Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. The comment period for this FDA Request for Information ibogaine will officially close on Friday, November 20, 2026, and any submissions received after this deadline will not be considered.

Lawyers advising pharmaceutical companies, research institutions, or investors in the psychedelic medicine space should alert clients to this Request for Information, as it presents a critical opportunity to influence the FDA's regulatory approach to ibogaine clinical trials. Submitting comments can help shape future drug development pathways and compliance requirements for novel treatments for mental health and substance use disorders.

Source: Original reporting via FDA announcement